Tags : Mbc

Pfizer’s Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA

Vartika Singh October 11, 2018

Shots: The approval is based on EMBRACA trial results assessing Talzenna (1mg) vs CT in 431 patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer for a duration of […]readmore

Pharma

Novartis’s Solar-1 trial BYL719 (PI3Ki, alpelisib) meets primary endpoints in

Vartika Singh August 24, 2018

Shots: In a global P-III combination of BYL719 + fulvestrant improved PFS vs fulvestrant in postmenopausal women and men with (HR+/HER2-) PIK3CA-mutant Breast Cancer that progressed on aromatase inh. ± […]readmore

Tags : Mbc

Pfizer’s Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA

Novartis’s Solar-1 trial BYL719 (PI3Ki, alpelisib) meets primary endpoints in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Mbc

Pfizer’s Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA

Novartis’s Solar-1 trial BYL719 (PI3Ki, alpelisib) meets primary endpoints in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company